Pharmacy First two years in: the thresholds, the caps, and making the service pay

Where does the service stand?

Pharmacy First is no longer a new service. Between April 2025 and January 2026 community pharmacies delivered over 2.75 million clinical pathways consultations, alongside nearly one million contraception service consultations and three million hypertension case-finding consultations, which places it firmly among the established elements of the contractual framework rather than among its experiments.

Two structural changes for 2026/27 confirm that position. The Pharmacy First budget, which previously funded the clinical pathways consultations, the Pharmacy Contraception Service and the Hypertension Case-Finding Service separately, has been fully merged into the core contractual sum, which guarantees the funding envelope to the sector. And independent prescribing is being introduced as an extension of Pharmacy First and the Contraception Service from autumn 2026, which represents the most substantial expansion of the service since it began.

What has not settled is whether an individual pharmacy earns from it. The service pays through a combination of a modest item fee, fixed payments awarded at activity thresholds, and monthly caps beyond which further activity attracts no fee, and that combination produces outcomes which surprise operators who model it as a simple fee per consultation. Two pharmacies delivering similar volumes may receive materially different sums, and the difference is frequently determined during the final week of a month.

How does payment actually work?

The item fee of £17 for clinical pathways consultations remains unchanged under the 2026/27 arrangements, and prescribing consultations within existing pathways are paid at the same rate as their PGD equivalents. The fixed payment arrangements are likewise maintained, with independent prescribing clinical pathway consultations counting toward the same thresholds.

Why are the thresholds cliffs?

The history behind those thresholds explains why they attract resentment as well as attention. The minimum activity requirement escalated substantially after launch, rising from five consultations per month during 2024 to thirty by March 2025, a trajectory raised in Parliament in February 2026 by a member describing a constituent pharmacy which never met the threshold and was therefore, in his characterisation, delivering the service for nothing.

That criticism is fair as far as it goes, and it identifies a genuine distributional effect, since a threshold system concentrates payment upon pharmacies able to reach it and pays nothing additional to those which cannot. It is worth observing, however, that the same structure rewards a pharmacy which organises deliberately around the thresholds considerably more than one which delivers the same total activity without regard to when it falls.

What do the caps do?

At the opposite end of the distribution sits the cap. Each pharmacy is assigned to a band carrying a monthly maximum number of clinical pathways consultations which attract the item of service fee, with band assignments and caps published each month by the NHSBSA, and activity above the cap attracting no fee.

For 2026/27 the cap arrangements are maintained, with an additional allowance made to each capping band for contractors delivering independent prescribing consultations, producing two caps within each band, one applying to pharmacies signed up for prescribing services and one to those which are not. Separately, the Government has indicated an intention to implement high-level caps for the hypertension case-finding service and the Pharmacy First minor illness service in order to restrict the highest-volume outliers, with details to be agreed during the year.

The practical implication is that Pharmacy First rewards activity within a range rather than without limit. A pharmacy substantially below its cap gains from each additional consultation, whilst one at its cap gains nothing further within the month and would be better served directing capacity toward services which are not capped, whether other commissioned services or the private work examined in the revenue playbook. Knowing which of those two positions applies requires reading the published band and cap rather than assuming, and the figures are republished monthly for that reason.

What are the gateway requirements?

Payment under the fixed arrangements is not available merely for delivering clinical pathways consultations. Eligibility requires the contractor to be registered for and able to deliver the Hypertension Case-Finding Service and the Pharmacy Contraception Service alongside Pharmacy First, together with the minimum activity requirement for the clinical pathways themselves.

Those requirements have accumulated. A minimum of one ambulatory blood pressure monitoring per month was added from October 2025, and a minimum number of contraception consultations was introduced from March 2026. The effect is that the fixed payment operates as a reward for a portfolio of services rather than for one, and a pharmacy delivering excellent Pharmacy First activity whilst neglecting ambulatory monitoring may forfeit the fixed payment entirely notwithstanding its clinical pathways volume.

For an owner reviewing whether the service pays, that structure repays checking before anything else, since the most expensive failure available is to deliver thirty consultations and receive no fixed payment because a single ambulatory blood pressure monitoring was not completed.

What does independent prescribing change?

From autumn 2026, independent prescribing enters the contractual framework as an extension of Pharmacy First and the Contraception Service. Community pharmacist prescribers will be able to prescribe within the existing Pharmacy First clinical pathways and the Contraception Service without requiring a Patient Group Direction, and to provide up to five new prescribing-only Pharmacy First pathways.

The conditions under consideration for those new pathways have been reported as bacterial conjunctivitis, allergic conjunctivitis, oral thrush, skin infections and respiratory tract infections. They are not yet settled, since the pathways require approval by a clinical reference group which NHS England is establishing, comprising principally pharmacists and general practitioners with input from other bodies including NICE.

Until the arrangements commence, the position is unchanged, in that all pharmacists providing the service must continue to use the PGDs and the clinical protocol. The prescribing route also depends upon the Electronic Prescription Service, which is an infrastructure requirement rather than a clinical one and warrants confirming rather than assuming.

The clinical case is straightforward. Prescribing within a consultation removes the ceiling which a PGD imposes upon what may be supplied, permits an alternative item where an individual patient's needs require one, and reduces the referrals back to general practice which a PGD-limited consultation generates. Evidence cited during the parliamentary exchange referred to a pathfinder pharmacy at which only five per cent of patients seen by prescribers subsequently required GP prescribing.

Does the prescribing arithmetic work?

The commercial case warrants examining more sceptically than the clinical one, and the sector's own commentary has done so.

The funding comprises a one-off set-up fee of £500 and a monthly infrastructure payment of £525, whilst the consultation fees do not rise, since prescribing consultations within existing pathways are paid at the same rate as PGD consultations. The fixed payment thresholds are likewise maintained, with prescribing consultations counting toward the same 20 and 30 consultation bands rather than toward higher ones. Commentary published following the settlement identified the consequence directly, observing that a pharmacy already reaching those thresholds through ordinary Pharmacy First activity gains no additional fixed payment from prescribing, which raises a genuine question about where the incentive sits for such a pharmacy.

The counter-argument is the capping allowance, since contractors delivering prescribing consultations receive an additional allowance within each band, which benefits precisely those pharmacies operating near their cap and which is where the incremental revenue actually resides. A pharmacy well below its cap gains little from prescribing beyond the infrastructure payment. A pharmacy at its cap gains headroom it could not otherwise obtain.

Funding is additionally not the only constraint. The Pharmacists' Defence Association identified workforce capacity, the suitability of pharmacy premises and safe staffing models as matters requiring attention if the expansion is to succeed, which is a reminder that a prescribing consultation occupies a qualified prescriber and a consultation room for a period which the £17 fee does not obviously purchase.

The honest summary is that the prescribing extension improves the service clinically and improves its economics selectively, benefiting capped high-volume pharmacies and those able to reach thresholds only with the additional pathways, whilst offering less to pharmacies whose constraint is demand rather than capacity.

What makes the service pay?

Five operational arrangements separate pharmacies for which Pharmacy First contributes from those for which it merely occupies.

Know the month-to-date figure weekly. Given that the twentieth and thirtieth consultations each carry approximately £500, the count is a pricing input rather than a report, and it must be visible early enough in the month to be acted upon.

Know the band and the cap. The published figures determine whether additional activity earns or does not, and they are republished monthly. A pharmacy operating at its cap should redirect capacity rather than continue.

Protect the gateway services. The ambulatory monitoring and contraception minima are small quantities of activity guarding a payment of up to £1,000, which makes them the highest-return tasks within the month and the ones most easily forgotten.

Convert referrals rather than awaiting them. The pathways depend upon patients presenting, and a pharmacy relying wholly upon referral routes will fluctuate around the thresholds rather than clearing them. The counter conversation, the visible offer and the local practice relationship are what convert an eligible presentation into a consultation.

Record and claim correctly. A consultation delivered and not claimed pays nothing, which is a more common failure than it should be within a service whose claim requirements have changed repeatedly.

What has changed about claims?

The claim window tightened during 2025/26, having been reduced to one month in order to enable the variable payment arrangements, which placed Pharmacy First among the small number of Advanced services operating a single-month window and made late claiming fatal rather than merely inconvenient.

Community Pharmacy England has since secured agreement that a later claim period will be re-introduced, with a two-month late claim window to be introduced during 2026, giving pharmacy owners a total of three months in which to claim. That is a material easing for pharmacies whose month-end processes have occasionally lost consultations, and it warrants confirming the implementation date rather than assuming the extended window is already available.

Two adjacent changes complete the position for 2026/27. New Medicine Service contractor caps have been adjusted down to 0.9 per cent of monthly prescriptions, reflected in the Drug Tariff for activity from June 2026. And the Pharmacy Quality Scheme continues with a reduced budget of £20 million and fewer requirements, with no clinical audits required, and with the aspiration payment increased from 75 to 80 per cent and payable on 1 September.

Key takeaways

FAQs